Read more about Georgia State University's innovation in research and scholarship.
The new university initiative establishes interdisciplinary research hubs to address some of society’s most pressing issues, including pandemic preparedness, climate solutions, crime victim protection, equity and access, and public health.
With $52 million in federal funding, researchers at Emory University and Georgia State University will establish a groundbreaking new drug development center aimed at preventing the next pandemic.
Former Provost Risa Palm and Associate Professor of Political Science Toby Bolsen have written a new article for The Conversation about their research into the attitudes of coastal homebuyers, even in the face of rising insurance premiums and even with flood maps showing sea level rise.
In this article for general audiences, Dr. Palm, Provost and Senior Vice President for Academic Affairs from 2009 to 2019, and her colleague explain their findings from their recent monograph/book, Housing Market Response to Sea-Level Rise in Florida (Springer, 2022).
You can read their article for The Conversation (republished under Creative Commons) by clicking the story link here at the Provost’s Office website.
transition, evolving a small-scale research operation into a powerful engine of discovery.
There wasn’t a single moment that sparked this dramatic transformation. Rather, years of collaboration and hard work by innovative faculty members, administrators and off-campus partners lay the groundwork for research success.
In 1996, Georgia State was designated an R1 university, and since then we’ve earned a place among the nation’s top research institutions. Take a look at the Georgia State University Research Magazine to see how we’ve grown into a leading, innovative, and interdisciplinary institution.
The COVID-19 pandemic and resurgence of infections by other respiratory RNA viruses such as respiratory syncytial virus (RSV) in children has caused an urgent need for the development of orally available broad-spectrum antiviral therapeutics.
In a study published online on Dec. 2 in Science, researchers in the Institute for Biomedical Sciences at Georgia State University report a new candidate ribonucleoside analog, 4’-fluorouridine (4’-FlU), that has potent antiviral activity against SARS-CoV-2, RSV and other respiratory RNA viruses in cell culture, human organoids and different animal models when administered orally once daily.
The Center for Translational Antiviral Research has been established in the Institute for Biomedical Sciences at Georgia State University to fill the gap for developing affordable, much-needed antiviral drugs that will reduce severe viral diseases and meet the threats imposed by existing and newly evolving viruses.
The research center will focus primarily on RNA virus pathogens of high pandemic potential, such as the coronaviruses, influenza viruses and paramyxoviruses such as Nipah virus. The center will focus on translating basic discoveries into applicable therapeutic candidates.
Send this to a friend
